IFN-α2b can be utilized for low-grade lymphomatoid granulomatosis (LYG), a rare nonmalignant lymphoproliferative disorder, and potentially prevent progression to overt lymphoma by augmenting the immune response to EBV. Here, IFNA2 is linked to lymphoma.